Multiple myeloma
Authors:
- 1 February 2000
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 1 (1) , 73-82
Abstract
Multiple myeloma (MM) is an incurable plasma cell dyscrasia that remains fatal. Despite efforts over the past 3 to 4 decades, the median survival of patients with MM does not exceed 3 to 4 years. Although patients receiving combination chemotherapy have higher response rates compared with those receiving oral melphalan and prednisolone, they have no survival advantage. High-dose chemotherapy followed by autologous stem cell transplantation has documented benefit over conventional treatment and is currently the accepted mode of treatment for symptomatic MM. Allogeneic transplantation is associated with high complete remission rates, but at the cost of high therapy-related mortality. Maintenance treatment with interferon-a shows benefit, albeit in a small fraction of MM patients. The use of bisphosphonates in patients with MM has clearly demonstrated benefit and reduced morbidity associated with bone disease. All of these measures have improved remission rates and survival, but all patients with MM ultimately relapse and succumb to their disease. Novel therapeutic strategies are therefore required to improve outcome of MM patients. The responses noted to thalidomide in MM are encouraging. Immune-based strategies, including both adoptive immunotherapy and vaccinations, are currently being investigated in the preclinical and clinical setting, with the goal of enhancing autologous and allogeneic anti-MM immunity for therapeutic applications.Keywords
This publication has 32 references indexed in Scilit:
- RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cellsOncogene, 1999
- Thalidomide — A Revival StoryNew England Journal of Medicine, 1999
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft?Bone Marrow Transplantation, 1998
- Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish RegistryBone Marrow Transplantation, 1998
- Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatmentBone Marrow Transplantation, 1997
- Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanismOncogene, 1997
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984